Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
Popok joined by guest anchor Adam Klasfeld of All Rise News (in for KFA), provide real time breaking legal and political news commentary about a federal judge blocking Trump's birthright citizenship attack again, a federal judge on the verge of holding Todd Blanche in Contempt related to the Epstein Files; a Trump insider deep inside his Administration providing new evidence directly to a federal judge about Trump's mail in ballot plot; and so much more at the intersection of law and politics. DOSE DAILY: Save 35% on your first month of subscription by going to https://dosedaily.co/LEGALAF or entering LEGALAF at checkout. SPRING SLEEP: Thanks to today's sponsor, Spring Sleep: eXciteOSA is an FDA-cleared, prescription-only device for primary snoring and mild obstructive sleep apnea. Go to https://springsleep.com/legalaf and unlock 20% off with the code LEGALAF IRONWALL: Stop online threats before they become real-world attacks. Visit https://ironwall.com/legalaf and request a free Risk Assessment to see exactly how exposed your executives are. DELETE ME: Get 20% off your DeleteMe plan when you go to join https://joindeleteme.com/LEGALAF and use promo code LEGALAF at checkout. Become a member of Legal AF YouTube community: https://www.youtube.com/channel/UCJgZJZZbnLFPr5GJdCuIwpA/join Learn more about the Popok Firm: https://thepopokfirm.com Subscribe to Legal AF Substack: https://michaelpopok.substack.com/labordaysale Remember to subscribe to ALL the MeidasTouch Network Podcasts: MeidasTouch: https://www.meidastouch.com/tag/meidastouch-podcast Legal AF: https://www.meidastouch.com/tag/legal-af Sidebar with Katie Phang: https://podcasts.apple.com/us/podcast/sidebar-with-katie-phang/id1886801652 The Parnas Perspective: https://podcasts.apple.com/us/podcast/the-parnas-perspective/id1869165949 The Intersection with Michael Popok: https://podcasts.apple.com/us/podcast/the-intersection-with-michael-popok/id1818863274 MissTrial: https://meidasnews.com/tag/miss-trial The PoliticsGirl Podcast: https://www.meidastouch.com/tag/the-politicsgirl-podcast The Ken Harbaugh Show: https://meidasnews.com/tag/the-ken-harbaugh-show The Weekend Show: https://www.meidastouch.com/tag/the-weekend-show Burn the Boats: https://www.meidastouch.com/tag/burn-the-boats Majority 54: https://www.meidastouch.com/tag/majority-54 On Democracy with FP Wellman: https://www.meidastouch.com/tag/on-democracy-with-fpwellman Uncovered: https://www.meidastouch.com/tag/maga-uncovered Five Minute News: https://podcasts.apple.com/us/podcast/five-minute-news/id1471715443 Learn more about your ad choices. Visit megaphone.fm/adchoices
Women's health is having a moment! The Cuntsultant, joins us for a rapid-fire tour through the biggest women's health updates: PCOS gets a name change, birth control myths, why endometriosis takes 10 years to diagnose, and the push for pain management during in-office procedures, ex. UDIs. Plus vaginal estrogen's life-saving role and why women outlive their ovaries. Women weren't studied or treated seriously and that's changing. Bring this one straight to your next appointment.✨ Special Offers: ✨Splash Blanket! | Use code Jordan15ProDx Health | Use JordanDnelle to save 25%Thank you to our Sponsors: Splash Blanket, Prodx, PhexxJump to the Good Stuff:06:30 – PCOS gets a better name07:35 – What's happening in your ovaries with PMOS14:26 – The metformin story that got reported to the medical board16:48 – The evolutionary theory that PMOS might be a genetic advantage19:03 – What birth control does to your hormones23:39 – Why endometriosis takes 10 years to diagnose30:15 – New endometriosis diagnostic breakthroughs in Europe34:29 – Why pain management for in-office procedures is being taken seriously39:35 – Vaginal estrogen's as recommendation for recurrent UTIs42:47 – The grandmother hypothesis - why we outlive our ovariesPleasure Highlights:PCOS has a new name: PMOSBirth control doesn't "regulate" your hormonesPain management for in-office gyno procedures is not offered upfrontVaginal estrogen now recommended for recurrent UTIsEndometriosis takes an average of 10 years to diagnoseConnect with The Cuntsultant:Instagram @cvntsultantWebsite: TheCuntsultant.comEnhance your self-awareness by acknowledging and understanding your behavior patterns, and foster a deeper connection with your inner self. Get the Unleashing My Power: A Women's Empowerment and Gratitude Journal to reclaim your power through daily gratitude. Learn more HERE.Connect with Jordan D'Nelle:Facebook @jordandnelleInstagram @jordandnelleInstagram @TheVVVPodcastTikTok @jordandnelleYoutube @jordandnelleWebsite: Jordan D'NelleEmail: JordanDnelle@VaginasVulvasandVibrators.comLove this Episode? Join the Patreon: patreon.JordanDnelle.comLeave a review on iTunes.Subscribe & Follow on socials!Listen and Subscribe to the Podcast:Apple PodcastSpotify PodcastYoutube @jordandnelle*Disclaimer: This podcast is for informational and/or entertainment purposes only and is not a substitute for medical advice, diagnosis, or treatment. The views and opinions expressed are my own, or those of my guests, and do not necessarily reflect the views of any organizations or institutions with which I am affiliated.Vaginas, Vulvas, and Vibrators, the unapologetic women's sexual wellness podcast, normalizing pleasure, bodies, and sexual health through expert, shame-free conversations.PhexxINDICATIONPhexx® is an on-demand prescription birth control used to prevent pregnancy. Phexx is not effective when used after sex.IMPORTANT SAFETY INFORMATIONRare cases (0.36%) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexx.Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.Phexx does not protect against any sexually transmitted infections, including HIV. Avoid using Phexx with a vaginal ring.Avoid Phexx if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the Ingredients in Phexx. Stop using Phexx If you develop an allergic reaction.For more information about Phexx, talk to your healthcare provider and see full Product Informationat www.phexx.com.Please report side effects by contacting Evofem Biosciences® toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.EVFM-PHX-000068
In this Supplement Ingredients Series episode, Nurse Doza breaks down phosphatidylcholine—the phospholipid that makes up much of every cell membrane you have. He explains why your liver and brain hold the biggest stores of it, how the liver uses phosphatidylcholine to package and move fat, and why choline is the precursor your brain needs for acetylcholine, the neurotransmitter behind focus and memory. He also shares the simple two-capsule morning routine he's used for years. FEATURED PARTNER BodyBio PC is a phospholipid complex—not a choline salt—which means it delivers phosphatidylcholine in the form your cell membranes are actually built from. That's exactly the distinction Nurse Doza draws in this episode: after cycling through different sources and forms over the years, this is the one that stuck. It's stimulant-free, and his routine is two capsules in the morning on an empty stomach.
Watch the show on television by downloading the SuperCrowd.tv Channel app to your Roku or Amazon Fire TV or e360tv channel app to your Roku, LG or Amazon Fire TV. You can also see it on YouTube.Devin: What is your superpower?Jason: I like to think that we are people with big brains and small egos. If we are high-impact, low-ego folks and we keep our eye on the ball, that's a recipe for success no matter what industry you're in.NextGen Scientific is turning an ancient Middle Eastern medicinal plant into a modern platform for cancer drug development and wellness products.In this episode, I spoke with Jason West, co-founder of NextGen Scientific, a PurposeBuilt100™ company recognized for combining growth with measurable impact. Jason explained that the company operates along two related tracks: Hyatt Life Sciences, its dietary supplement business and Genzada Pharmaceuticals, its drug discovery and development company.The common thread is chemistry.Jason described the company's work with Arum palestinum, a plant that grows wild in the Middle East and has long been used there as a tea. That history is what pulled the scientific team in.“What caught our attention was that there are references to the use of this plant as a medicinal plant going all the way back to the 9th century AD,” Jason said. “For 1,100 years, it's been in continuous use.”That kind of longevity raised a serious scientific question for the team: why would people keep using it for more than a millennium if there were no benefit? Jason said NextGen began studying naturally occurring molecules in the plant, ultimately identifying compounds that became the basis for its oncology research.The company now has two lead oncology or oncology-related drug candidates. One is an oral capsule in clinical trials at Virginia Commonwealth University for late-stage prostate cancer, with trials expected in the Netherlands and Sweden. The other is a topical cream aimed at actinic keratosis, a precancerous skin condition with tens of millions of cases annually in the United States.Jason emphasized that the goal is not to replace oncologists but to help them. “We feel like we can be just one more tool in the toolbox of the oncologist, and that's what our ultimate goal is,” he said.Congratulations to NextGen Scientific LLC on ranking #46 on the 2026 PurposeBuilt100™ list! We're proud to recognize the company among America's fastest-growing mission-driven businesses, celebrating the connection between purpose, innovation, and growth. Meet the Class of 2026 — see the full list of winners →What I found especially compelling is the company's dual-path strategy. Drug development can be slow, expensive and risky. By building a supplement business alongside the pharmaceutical pipeline, NextGen has created revenue while continuing the long FDA-focused journey.That strategy emerged organically. In rural Kansas, word spread that the family was working with a tea tied to cancer wellness. People began asking for it. “By the end of the day, I think we were sending about 40 gallons of this tea out a week just to friends and family,” Jason said.NextGen Scientific is currently raising capital through a Regulation D offering for accredited investors, targeting just over $10 million. Jason said proceeds will help accelerate clinical trials, open new trial fronts and support marketing for the supplement business.It is exactly the kind of purpose-built growth story I love to celebrate.tl;dr:Jason West's team is translating an ancient Middle Eastern plant into cancer drugs and supplements.NextGen Scientific pairs Genzada Pharmaceuticals' clinical pipeline with Hyatt Life Sciences' wellness products.Small-town curiosity created unexpected demand, eventually reaching roughly 40 gallons of tea weekly.A Regulation D raise seeks just over $10 million from accredited investors to accelerate trials.Low-ego brilliance helps Jason keep hard conversations focused on data, kindness and learning.How to Develop Low-Ego Brilliance As a SuperpowerJason's superpower is Low-Ego Brilliance. He describes it as being among people with “big brains and small egos.” For Jason, the combination matters because “if we are high-impact, low-ego folks and we keep our eye on the ball, that's a recipe for success no matter what industry you're in.” He connects the idea to persistence, humility and disciplined focus: “You just have to keep on putting one foot in front of the other.” His advice is simple but powerful: “Take the phone call. Always take the phone call.”Jason shared a story about meeting with an exceptionally smart but highly skeptical person who seemed to have little patience for NextGen's science. Rather than taking offense or trying to win a personality contest, Jason and his team stayed calm and redirected the conversation to the data. A meeting scheduled for 15 or 20 minutes stretched to about two hours. By the end, the skeptic had become a friend. Jason summed up the lesson this way: “If you have the data on your side, you don't need to be too big for your britches.”Build teams with big brains and small egos; value impact over status.Keep your eye on the ball, especially when the work is long and difficult.Put one foot in front of the other rather than demanding instant success.When challenged, redirect the conversation to evidence instead of emotion.Be kind to skeptics; you can catch more flies with honey than vinegar.Take the phone call when you can because there is almost always something to learn.Stay curious, not judgmental, especially when you assume a conversation will not matter.By following Jason's example and advice, you can make low-ego brilliance a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileJason West (he/him):Executive Vice President, NextGen ScientificAbout NextGen Scientific: NextGen Scientific is a biotechnology and life sciences company dedicated to advancing innovative oncology research and developing evidence-based therapeutic solutions. Focused on cancer research, tumor biology, precision therapeutics, and plant-based pharmaceutical and bioactive compounds, the company works to bridge the gap between scientific discovery and real-world healthcare impact. Through translational medicine, preclinical research, intellectual property development, and a disciplined, research-driven approach, NextGen Scientific is building novel, scalable solutions designed to advance the future of cancer care and therapeutic innovation.Operating at the intersection of biotechnology, healthcare innovation, and commercial strategy, NextGen Scientific has developed a dual-entity model that combines biotechnology development with a revenue-generating wellness platform. Alongside its oncology pipeline, the company brings science-backed nutraceutical and metabolic wellness products to market, creating a sustainable engine to support continued research and growth. As NextGen Scientific expands its oncology pipeline, patent portfolio, and commercialization strategy, it remains focused on translating promising science into safe, effective, and impactful health solutions.Website: investinnextgen.comLinkedIn: linkedin.com/company/nextgen-scientificBiographical Information: Jason West is a seasoned executive and entrepreneur with extensive leadership experience across biotechnology, pharmaceuticals, life sciences, chemicals, and business development. He currently serves as Executive Vice President of Genzada Pharmaceuticals and NextGen Scientific, while also serving as Chairman of Geo-Chemicals, LLC and Chief Executive Officer of Hyatt Life Sciences. His career reflects a strong combination of scientific knowledge, legal expertise, and executive leadership, with a focus on building and guiding organizations at the intersection of science, innovation, and commercial growth.Earlier in his career, Jason spent 15 years with Jacam Chemical Company, including more than seven years as President and seven years as Vice President and General Counsel. He holds a Bachelor of Science in Biology from Sterling College, a Juris Doctor from Vermont Law School, and an MBA from Northwestern University's Kellogg School of Management. With experience spanning scientific research, law, corporate leadership, and strategic management, Jason brings a multidisciplinary perspective to advancing innovative businesses and life sciences initiatives.LinkedIn: linkedin.com/in/jason-west-b33b7a163Watch the Impact Stories on BIG Screen!Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include PurposeBuilt100™ Winners and supercrowd.tv. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Eric Coury, Arthia AI | Joey Hayes, thru | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Ken Steele, Rotarian | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Mark Grimes, Networked Enterprise Development | Mike Babbit | Coledger Solutions | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Join the SuperCrowd Impact League! You can be recognized for making impact investments via Reg CF. See how your activity compares to your peers. It's free. Win valuable prizes. Start now!SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on September 8th at 8:00 PM ET/5:00 PM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!Apply for the Superpowers for Good Live Pitch: Are you raising capital through Regulation Crowdfunding? Apply by September 2 for the September 30 Superpowers for Good Live Pitch. Selected founders pitch free to investors and gain exposure through SuperCrowd.tv, e360tv, social media, and our 10,000-subscriber newsletter. We especially encourage social entrepreneurs, women and underrepresented entrepreneurs to apply.Visit Our Complete Community Event CalendarIf you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We share educational information—not investment advice. Some links may generate compensation. See our full disclosure.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe
For millions of young women and girls, often the first place they turn with questions about their bodies isn't a doctor's office, it's social media which can lead to encountering many misconceptions and outright misinformation. Or, if the right voices show up, it can mean something else entirely. Our guest today, Dr. Charis Chambers, is one of those voices. She's a board-certified OB/GYN with specialty certification in Pediatric & Adolescent Gynecology, and Chief Medical Officer at Clue, a leading period and cycle-tracking app. She's also the founder of The Period Doctor, a platform she launched in 2019 to provide medically accurate reproductive health information and to place more minority physicians in the spaces where patients are already looking for answers. As she tells Raise the Line from Elsevier host Lindsey Smith, Dr. Chambers embraces the role of being a bridge between generations: "I can serve as a medical mediator where I advocate for the child and then educate the parent so that the child's concerns are met." Stay tuned to this important conversation to also learn about: Her new book, The Period and Puberty Parenting Revolution, which tackles many of the same myths she encounters every day in her clinic; Why stubborn myths around periods rarely hold up once you ask where they come from; How she thinks about the responsibility, and limits, of being a trusted medical voice on social media. Mentioned in this episode: Clue The Period Doctor The Period and Puberty Parenting Revolution If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss advancement in Alzheimer's testing and practical uses of artificial intelligence (AI) in healthcare. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories' chief digital innovation officer, to explore the evolving role of data in research and development. Innovative Alzheimer's test gets FDA clearance (00:33): Dr. Morice shares how a strategic collaboration is enabling Mayo Clinic Laboratories to offer a newly FDA-cleared blood test for Alzheimer's disease for adults with cognitive symptoms as young as 40.AI helping diagnose rare diseases (03:37): Dr. Pritt and Dr. Morice reflect on a recent article highlighting how AI is helping clinicians identify rare diseases.Data use in research and development (08:16): Dr. Garcia discusses how data, AI, and cross-disciplinary collaboration are advancing research and innovation in laboratory medicine. Note: Information in this post was accurate at the time of its posting.ResourcesC2N Diagnostics: FDA clears C2N Diagnostics' PrecivityAD2® —First Alzheimer's blood test for adults with cognitive symptoms as young as 40Wall Street Journal: AI is helping patients solve medical mysteriesAnswers From the Lab: Digital Advances: What's Next for Clinical Diagnostics?Answers From the Lab: Accelerating Research and Development With BioPharma Diagnostics
Tiger Woods loses his license for 5 years, Lionel Ritchie is out of the hospital, Lindsay Clancy jury still deadlocked, Bill Clinton recently held his star-studded 80th birthday party, Ron DeSantis endorses Byron Donalds, Trumps gold coin is being released, Lab grown food that has been approved by the FDA, and dumb adults fight at kid's sporting events...
On Monday the Supreme Court let the President keep building a 400 million dollar ballroom on the White House grounds. It did not rule that the ballroom is legal. It ruled that the people who sued could not prove they were injured enough to be allowed through the door, and Chief Justice John Roberts dissented and called the project likely unlawful. Nobody has ruled on that question. Nobody may ever rule on it. That is the thread running through this entire episode. The check still exists on paper. The question is whether anybody can actually reach it. In Trump Corruption Watch, newly renamed because this beat covers a lot more than money: the Venezuela oil concession, where Trump announced majority US control of more than 65 billion barrels at what he called no cost to the American taxpayer. I break down the actual structure, a 100 year concession granted by an interim government the United States installed by force in January, with the US holding 55 percent of a joint venture whose private partner still has not been publicly named. Then the ballroom ruling and what standing doctrine actually means for every citizen lawsuit against the federal government. Then the final USPS mail ballot rule, the 24 state lawsuit, and a whistleblower disclosure released by Senator Blumenthal alleging the agency raced an untested ballot portal toward launch six weeks before the midterms. Then Pete Hegseth pulling at least 45 officers off Army promotion lists this year, more than half of them women or Black officers, and the Republican congressman who defended it by saying we serve at the goodwill of the President. I also open with a correction from the August 26 show, because I got ahead of the evidence on the airport trademark story and that is on me. In Nuanced News: the strike on Larak Island in the Strait of Hormuz and why Congress reached the war powers check twice, with Republicans crossing both times, and picked a vehicle that could not bind anything. The 50 percent Canada tariffs running on a 96 year old law no court has ever tested, because nobody can afford to sue. And a Seventh Circuit ruling almost every outlet flattened, where a federal judge told the Supreme Court he can see the problem and is not free to fix it. Plus Research on a Dime on the Senate math and Ed Markey beating Seth Moulton while badly outspent, a listener question from Iowa's 2nd District about four candidates on the ballot and only two on the debate stage, and Good News including the first FDA approved drug targeting the mutation behind most pancreatic cancers. CHAPTERS 00:00 Cold open 01:46 Welcome and the thread running through tonight 03:38 Clip: the AI generated fake political commentator networks 07:41 Trump Corruption Watch, and why the segment got renamed 09:05 Correction from the August 26 show 10:35 The Venezuela oil concession and the partner nobody will name 19:53 The White House ballroom and the 5 to 4 ruling 26:07 The USPS mail ballot rule and the whistleblower disclosure 37:08 Hegseth and the Army promotion boards 44:03 Iran, Larak Island, and the war powers vote that could not bind 52:50 The Canada tariffs nobody is suing over 58:26 The Seventh Circuit ruling almost everyone flattened 1:05:08 Quick hits: Ukraine, data centers, Meta, Flock, hush money 1:09:43 Research on a Dime: the Senate arithmetic 1:10:49 Massachusetts: Markey beats Moulton 1:12:30 Breakdown in the Public: Iowa's 2nd District debate access 1:18:45 ALIVE Podcast Network 1:19:28 Good News the media does not talk about 1:23:18 Close Got a story you want covered? Email thetrendgoldandfaith@gmail.com Share your own political solutions: https://www.reddit.com/r/policysolutions/ RESOURCES Podcast website: https://www.purplepoliticalbreakdown.com ALIVE Podcast Network: Catch a lot of great podcasts like my own, led by amazing Black voices. https://alivepodcastnetwork.com/ Living Room Conversations: Building bridges through meaningful dialogue across political divides. https://livingroomconversations.org/ Us United: A movement for unity that challenges Americans to step out of their bubbles and connect across differences. https://www.us-united.org/ OtherWeb: An AI based platform that filters news without paywalls, clickbait, or junk. https://otherweb.com/ Equal Vote Coalition and STAR Voting: Voting methods that ensure every vote counts equally. https://www.equal.vote/star Substack: https://open.substack.com/pub/purplepoliticalbreakdown All links: https://linktr.ee/purplepoliticalbreakdown Join the Discord: https://discord.gg/ptPAsZtHC9 Political solutions without political bias.
130. Psilocybin and Menopause: Two Clinicians Reframe Midlife for WomenEpisode SummaryEstrogen regulates the serotonin system, and psilocybin reaches the same receptor. That is where this Salon starts, and it is the most specific version of the psilocybin and menopause conversation I have heard in public.Kelly McGinty, a nurse practitioner, told a full room at Town Hall Seattle that the drop women feel in perimenopause is physiological rather than imagined. I asked whether that means psilocybin replaces estrogen. She said no, and that she would like more research. Her co-author, Dr. Trish Singh, added that research on menopausal women barely exists at any phase of the transition.Two clinicians describe what they see in their patients, then draw a line at the point where the evidence ends. Most people selling a reframe of midlife will not draw that line on a microphone.What sits on the other side of it: anxiety as a knock on the door rather than a malfunction, why women microdose intuitively instead of on a protocol, and the archetypes we inherit about aging women. Kelly's oldest client is 85, and she says the younger generation is watching to see how the older one heals.A woman in perimenopause deserves an explanation for what is happening in her body. Psilocybin is not what delivers that. A provider who knows the full symptom list is.
This week, Marianna sits down with John Faragon to talk about the recent approval of Bictegravir and Lenacapavir (or BIC/LEN) and the FDA label. Tune in to learn all about what it is and why it matters to you as an HIV care provider. -- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=EPP8742)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: https://www.necaaetc.org/self-paced-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=US Apple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691
What if “Satan's throne” wasn't a metaphor? Jonathan Cahn reveals the astonishing mystery of the Altar of Pergamon, unearthed in Turkey, transported to Berlin, and linked to Hitler, the Holocaust, Soviet communism and nuclear Armageddon. Is an ancient spiritual power still shaping history—and our world today? GUEST: Jonathan Cahn is a New York Times bestselling author, biblical teacher and one of the world's most recognized voices exploring the intersection of Scripture, prophecy and world events. His bestselling books include The Harbinger, The Oracle, and The Return of the Gods. In his latest book, The Altar of Pergamon, Cahn investigates what he believes is an extraordinary biblical and historical mystery surrounding the ancient altar associated with Pergamum—the city identified in Revelation as the place “where Satan has his throne.” His investigation traces provocative connections from the altar's excavation and removal to Berlin through the rise of Hitler and Nazism, the Holocaust, Soviet communism, the Cold War and the nuclear age. Cahn's work asks a provocative question at the heart of Strange Planet: Could unseen spiritual forces be operating behind the rise and fall of nations—and could the mystery of Pergamon still be unfolding today? WEBSITE: https://www.hopeoftheworld.org/ BOOKS: The Altar of Pergamon: The Mystery of the Dark Angel and the Future of the World The Avatar The Dragon's Prophecy The Josiah Manifesto The Harbinger ll: The Return The Return of the Gods The Book of Mysteries The Oracle The Mystery of the Shemitah The Paradigm The Harbinger FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet SUPPORT OUR SPONSORS!!! HIMS Weight Loss By HIMS -HIMS now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy® pill and the Wegovy® pen. Ready to reach your goals? Visit hims.com/strangeplanet to get a personalized, affordable plan that gets you. MARS MEN Mars Men helps you reclaim your edge with natural testosterone support for energy, focus, and strength Go to MenGoToMars.com right now, for a limited time, listeners of this program get 50% off for life, plus free shipping AND 3 free gifts. QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. CARGURUS CarGurus is the #1 rated car shopping app in Canada on the Apple App and Google Play store. They've got hundreds of thousands of cars from top-rated dealers, plus advanced search tools that let you zero in on exactly what you want. And you can set real-time alerts for price drops and new listings — so you never miss a great deal. Buy your next car today with CarGurus at cargurus dot ca. Go to cargurus dot ca to make sure your big deal is the best deal. BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit https://strangeplanet.supportingcast.fm Use the discount code "Planet" to receive $5 OFF any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/
The World reports from on the ground in one of the hardest-hit districts of Nepal from recent flooding. Also, tributes honoring the former Bosnian Serb commander Ratko Mladić, who died last week while serving a life sentence at The Hague for genocide and war crimes, have caused outrage across much of Bosnia and Herzegovina. And, Mexico pushes back against the FDA narrative that a major Cyclospora outbreak in the US originated in Mexico, as scientists say that the exact point of contamination is still unclear. Plus, national weather agencies across the globe are increasingly turning to AI to for more accurate forecasts. Learn about your ad choices: dovetail.prx.org/ad-choices
On this episode of Vitality Radio, Jared and Jen sit down with clinical psychologist Dr. Roger McFillin for a challenging conversation about psychiatric diagnosis, mental health medications, and the medicalization of normal human struggle. Jen shares her experience of being prescribed Prozac at age 13 and spending decades living under diagnoses that shaped how she saw herself. Dr. McFillin explains why he has become an outspoken critic of his own profession and questions how conditions such as depression, anxiety, bipolar disorder, and ADHD are diagnosed. They discuss the DSM, informed consent, psychiatric medications, emotional suppression, personal agency, and the powerful effect a diagnosis can have on identity. This conversation asks an important question: Are we helping people understand why they are struggling, or simply giving their struggles a name?Additional Information:Dr. Roger McFillin - Website + Podcast Dr. Roger McFillin Instagram Dr: Roger McFillin on X Dr. Roger McFillin Substack Center for Integrated Behavioral Health Jen's Story Episodes:264: Emotional Vitality423: Emotional Vitality: Jen's Story Part 2 - Rebalancing Mind and Body Through Supplementation438: Emotional Vitality: Jen's Story Part 3 - Weaning Off of Pharma457: Emotional Vitality: Jen's Story Part 4 - How Changing Your Mindset Can Change Your Life 505: Emotional Vitality: Jen's Story Part 5 - The Impact of Diet on Mental Health and Physical PainVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.comhttps://drtalks.com/podcast-service/
In a world quick to prescribe electrical violence to the brain under the guise of “treatment,” it is a profound relief—and a moral imperative—to sit down with one of the clearest voices challenging this relic of psychiatric barbarism. On The Breggin Hour, my husband Peter Breggin and I spoke at length with Professor John Read, a clinical psychologist from the University of East London whose work has helped pierce the veil of denial surrounding electroconvulsive therapy (ECT). Professor Read is no outsider throwing stones. He comes from the heart of the clinical psychology establishment, yet he has become one of its most formidable critics on ECT. His recent international survey—the largest ever, with 1,100 participants from 44 countries—gives voice to the lived reality of those who have endured this procedure. The findings are damning. What the Largest ECT Survivor Survey Reveals The research team, which included ECT survivors like our colleague Sarah Hancock, asked hard questions about efficacy, memory loss, and informed consent. The results: On five different measures of effectiveness, the “majority” of recipients reported “no improvement” or that their condition was “made worse”. Two-thirds experienced significant memory loss—both retrograde (losing past memories) and anterograde (inability to form new ones). For most, this persisted for at least three years, which in practical terms means it is often permanent. The vast majority were not adequately informed about these risks. Neither were their families. Women continue to receive ECT at twice the rate of men, with 82% of the psychiatrists administering it being male—an observation that raises uncomfortable questions about power, empathy, and whose distress we choose to “treat” with electricity. These are not abstract statistics. They represent shattered lives, erased memories, and families left picking up the pieces. As Peter has long documented, ECT is essentially a closed-head electrical lobotomy that exceeds OSHA safety thresholds for electrical brain injury. The brain is not “reset”—it is traumatized. Professor Read put it plainly: we are inducing grand mal seizures in people while another branch of medicine works desperately to prevent them. The original 1930s theory—that schizophrenia and epilepsy were mutually exclusive, so inducing seizures could cure the former—was bizarre even then. That we continue this practice ninety years later, with so little rigorous evidence, is a scandal. Legal Victories: Hitting Them Where It Hurts Professor Read has served as an expert witness in key cases that are finally forcing accountability. In a 2023 Florida jury trial, manufacturer Somatics was found liable for failing to adequately warn about brain damage and permanent memory loss. A 2024 California case against individual psychiatrists and a psychiatric center—alleging negligence, fraud, malpractice, and battery—settled just before trial after surviving all dismissal attempts. MECTA, another major manufacturer, has filed for bankruptcy amid mounting litigation and withdrawn its Spectrum device, only to introduce a near-identical “Sigma” model. The industry adapts, but the human cost remains. Peter shared his own observations from decades of work, including the first successful ECT malpractice case (Salters, 2005). He described the visible horror: patients emerging confused, amnesic, and disoriented—much like victims of repeated concussions. This is traumatic brain injury, period. The temporary “euphoria” some experience is often the brain's response to injury, not genuine healing. The Deeper Problem: Over-Medicalization of Human Suffering John Read situates ECT within a larger tragedy—the reduction of complex human distress to a purely biological problem solvable by pills or electricity. Poverty, trauma, abuse, loneliness, and loss are pushed aside while white coats reach for the shock machine. Many psychiatrists, he notes, lack the skills or willingness to sit with profound emotional pain, especially in women and older patients. This resonates deeply with our work exposing psychiatric harm. Whether antidepressants, antipsychotics, or ECT, the pattern is the same: interventions that promise quick fixes but deliver dependency, disability, and despair. The public understands that life circumstances drive mental suffering. Too many professionals still do not. A Call to Survivors, Families, and Truth-Seekers If you or a loved one has been harmed by ECT, know that you are not alone. Professor Read's survey papers are open access—search “John Read ECT survey” to read them directly. Share your story. Support organizations fighting for informed consent and bans on this outdated practice. We must demand real informed consent, rigorous science, and an end to the normalization of brain damage as “therapy.” Peter and I continue this fight because human rights do not end at the psychiatrist's door. The brain is not a machine to be jolted into submission. Listen to the full conversation on The Breggin Hour (available on America Out Loud and major podcast platforms). Professor Read's humility, clarity, and dedication shine through. We are grateful for his partnership in this long struggle and look forward to future collaborations. Download and print this free brochure “No One Should Be Given Shock Treatment“ To all who have suffered: Your experiences matter. Your memories—however fragmented—are worth fighting for. The truth is emerging, one voice, one lawsuit, one honest conversation at a time. Share this widely. The more light we shine, the harder it becomes for these practices to hide in the shadows. Peter and Ginger Breggin have spent decades exposing psychiatric harms. Subscribe for more unfiltered truth on mental health, freedom, and the defense of the human spirit. About our Guest Dr. John Read is Professor of Clinical Psychology at the University of East London. He has published over 200 research papers, primarily on the relationship between adverse life events and psychosis; the negative effects of bio-genetic causal explanations on prejudice; anti-psychotic and anti-depressant medication; electroconvulsive therapy; and the toxic influence of the pharmaceutical industry on clinical research and practice. John is Chair of the International Institute for Psychiatric Drug Withdrawal [https://iipdw.org] and is on the Board of Hearing Voices Network, England He has been the editor of the scientific journal ‘Psychosis' since 2009, and is the editor/author of several books, including: Read J, Sanders P. (2022) ‘A straight talking introduction to the causes of mental health problems'. PCCS Books. Read J, Dillon J. (eds) (2013) ‘Models of Madness', Routledge. Further Reading/Resources: Professor John Read's publications: A large exploratory survey of electroconvulsive therapy recipients, family members, and friends: what information do they recall being given? Journal of Medical Ethics A Survey of 1144 ECT Recipients, Family Members and Friends: Does ECT Work?, National Institutes of Health Largest-ever survey questions ECT's effectiveness, University of East London Survey Findings on Electroconvulsive Therapy, Psychology Today Models of Madness and Other Works by John Read By Peter R. Breggin, MD: Download and print this free brochure “No One Should Be Given Shock Treatment“ Free Resource Center: Dr. Peter Breggin's ECT and Deep Brain Stimulation Resources Center Dr. Breggin's two overview scientific articles: Breggin 1998 and Breggin 2010. The 2010 article contains a brief summary of ECT's harmful effects, written to inform the FDA. Also read Jones and Baldwin 1992 for a powerful overview. Read Dr. Breggin's blogs on ECT. Like the brochure, these are also useful as an introduction for anyone who is just learning about ECT. See his blogs: “New Study Confirms Electroshock (ECT) Causes Brain Damage,” “The Stealth ECT Psychiatrist in Psychiatric Reform,” “FDA Panel Recommends Testing of ECT Machines,” “Electroshock for Children and Involuntary Adults.”
This week on On The Pen, the GLP-1 story is moving in two very different directions.The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its consumer guidance around compounded GLP-1 medications and multi-dose vials, and employers continue questioning whether they can afford obesity-drug coverage.At the same time, the medical case for these medications keeps getting stronger.We break down Mounjaro's new cardiovascular indication and what preventing heart attacks and strokes could mean for the true long-term cost of GLP-1 treatment. We also look at 600,000 Medicare beneficiaries already enrolling in the $50 GLP-1 Bridge program, California's effort to tackle affordability, the rapidly expanding oral GLP-1 market, and new real-world data on patients staying at lower doses of semaglutide and tirzepatide.The science is expanding. Access is contracting.And that may be the biggest challenge facing the next phase of the GLP-1 revolution.In this episode:• What the Fifth Circuit compounding decisions actually mean• FDA's updated language around compounded GLP-1 vials• The 28-day multi-dose vial controversy• Mounjaro's new cardiovascular indication• Why GLP-1s may reduce long-term healthcare costs• Employers dropping obesity-drug coverage• 600,000 people joining the Medicare GLP-1 Bridge• California's push for lower GLP-1 prices• The oral GLP-1 race• New data on lower-dose semaglutide and tirzepatideFollow everything On The Pen:This episode is sponsored by VoaFit.https://www.voafit.com/otpThis content is for informational and educational purposes only and is not medical advice. Always discuss medication and treatment decisions with a qualified healthcare professional.
Medical device regulation continues to evolve across multiple markets. For manufacturers, the challenge isn't simply following every new publication—it's understanding which developments require action, which ones need monitoring, and how they affect existing regulatory strategies.This latest Medical Device Made Easy regulatory update reviews selected developments from July and August 2026 across Europe, Switzerland, the UK, United States, India, Singapore, and Brazil.
Insomnia affects neurologic health, quality of life, and daily functioning, but effective treatments are available. In this episode, Dr. Brandon Peters-Mathews discusses a practical approach to evaluating chronic insomnia, highlights the importance of identifying contributing conditions such as sleep apnea and mood disorders, and reviews cognitive behavioral therapy for insomnia (CBT-I), the recommended first-line treatment. Learn how addressing sleep can improve outcomes across a wide range of neurologic disorders. In this episode, Katie Grouse, MD, FAAN, speaks with Brandon R. Peters-Mathews, MD, FAAN, FAASM, author of the article "Insomnia" in the Continuum® August 2026 Sleep Neurology issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California, San Francisco in San Francisco, California. Dr. Peters-Mathews is the Section Head of Sleep Medicine at Virginia Mason Franciscan Health in Seattle, Washington. Additional Resources Read the article: Insomnia Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @BrandonPetersMD Full episode transcript available here Dr Grouse: Insomnia may be one of the most common medical issues experienced by patients, yet our knowledge about how to manage it remains limited. Today, I have the opportunity to speak with one of the world's leading experts on sleep disorders, Dr. Brandon Peters-Mathews, about the latest issue of Continuum on Neurology of Sleep. Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr. Katie Grouse. Today, I'm interviewing Dr. Brandon Peters-Mathews about his article on insomnia. This article appears in the August 2026 Continuum issue on Neurology of Sleep. Welcome to the podcast, and please introduce yourself to our audience. Dr Peters-Mathews: It's my pleasure to join you, and I'm happy to talk about this article. I think it's an interesting one for most folks. I am a board-certified sleep neurologist. I practice at Virginia Mason Franciscan Health in Seattle. I did my neurology training back at the University of Minnesota and my sleep training at Stanford University. I've been in practice for more than thirteen years at this point. It's hard to believe, but it's exciting to be able to speak with you today. Dr Grouse: This is definitely an important topic for everybody. Certainly, sleep and the lack of it affects all of our patients, and I can't imagine there's a single clinical neurologist who doesn't have to answer questions and help evaluate patients with this problem, so very high-yield topic for everyone. Now, having read your article, I'm curious if you had to choose one key point that you want the readers of your article to take away after reading it, what would it be? Dr Peters-Mathews: Emphasize for my patients that insomnia is a condition that we can work through and resolve, that if we really can understand the underlying contributing causes and resolve those issues, we can typically improve sleep. It's a process. It takes time. It takes some attention and, and sometimes even testing to figure out what's going on. But if we can dial into these root causes, we can typically help somebody to sleep much better. As part of that, we often employ a therapy called CBT-I, which we'll talk about here a little bit later. But that also helps us to identify some of these contributing factors that are leading to the poor sleep. Dr Grouse: And I definitely want to talk more about CBT, it's such an important topic. But even before we get into that, I'd love it if you could just walk us through a hypothetical case of a patient with insomnia. I think the type of patient that I think we've all seen in our clinical practice and somebody who says, "You know, I've had poor sleep. I've had insomnia for many years. I've tried all of the things you're supposed to try. You know, I've tried sleep hygiene. I've tried this. I've tried that. I've tried medications. Nothing seems to work." Could you walk us through how you would evaluate a patient like this and start to consider what to recommend? Dr Peters-Mathews: So, some simple information that we can gather, would be information about when they're trying to go to bed, how long it's taking them to fall asleep initially. If they wake in the night and have trouble getting back to sleep, how often they wake in the night. If they're experiencing early morning awakenings, their final wake time, and when they actually get out of bed in the morning. That gives me a sense of the structure of their sleep pattern and whether or not they might be spending an excessive amount of time in bed for their own sleep need at their current age. The other factors that we might consider are sleep disorders, and typically, I would assess for other symptoms that would point me towards sleep apnea or restless legs and occasionally other disorders of sleep. We wanna make sure we're not missing comorbid conditions that might be affecting that person. These often include mood disorders. Sleep and mood walk hand in hand, and so anxiety and depression are important to identify and treat if present. We also want to make sure someone's not suffering from chronic pain or other conditions that might be impacting their sleep. So, I take a broad approach. I ask the same questions to each patient that comes to see me. I wanna make sure I'm not missing some of these details. And then some of these folks will require testing to further understand their sleep. Others may move on to a different therapy, and long-term may require even other interventions, including medications, to fully resolve their condition. Dr Grouse: You mentioned in your article circadian rhythm sleep disorders. How often are these really a factor in patients with chronic insomnia? And do you think that's something that we as kind of first-line clinicians should be screening for as well? Dr Peters-Mathews: So delayed sleep phase syndrome is the most common circadian disorder, and these are folks who are night owls by nature. They often develop their sleep patterns, as teenagers, if not before, and they may fade away in the working years but come back in retirement age. I would say that's a very common condition. It may affect as many as one in ten people. The other circadian disorders are pretty uncommon, so advanced sleep phase syndrome, where somebody is sleepy early and waking too early, that may only affect one in three hundred people. There are other conditions that affect specific populations, like non-twenty-four circadian pattern affects blind people. Typically, half of blind people have that condition. There are conditions that affect the regularity of sleep, so an irregular sleep-wake pattern that might occur more in folks with maybe an advanced dementia. So, there are populations where these conditions can be fairly common, but among the general population, that night owl tendency is by far the most common. Dr Grouse: That's really helpful. And just taking a step back, why is insomnia bad for us? So, we worry about this in our patients. We know it can make neurologic issues worse. But in general, like, what are the reasons that having poor sleep can affect our health? Dr Peters-Mathews: Yeah, and it's not enough hours, certainly quantity, but also quality of sleep that matters. And I tell people that sleep is a pillar of health, just like nutrition and exercise. It's the other main contributor to our health and well-being. And so, it has its fingers in almost every aspect of our health. Insomnia on its own is a risk factor for other psychiatric conditions, including depression, anxiety, even disorders like bipolar and schizophrenia. Folks with insomnia are more likely to have alcohol or drug abuse issues and are at higher risk for things like chronic pain, suicide and, and social and occupational dysfunction. So, it's a disorder that has a really profound effect on how someone functions during the day, and again, may take a toll on their health over time. Dr Grouse: That makes sense, and I would assume that there are certain populations within our neurology practices where we should really be attuned to the risk of insomnia. Are there specific populations you'd recommend really make it a habit of screening for insomnia? Dr Peters-Mathews: I was joking with someone recently that anyone with a neurological nervous system can have issues, impacted by poor sleep. There are certain groups, so chronic headache patients are perhaps one that might warrant a further evaluation and management. Folks with multiple sclerosis or Parkinson's may have physical conditions that lead to more discomfort in sleep, fewer movements of their body in sleep, issues around nocturia that would disturb their sleep. Certainly, those with dementia, Alzheimer's disease and other dementias. Parkinson's and Lewy body dementia overlap a lot, as does multiple system atrophy. That can point us towards other conditions like REM sleep behavior disorder, but also insomnia can be an important feature of those disorders as well. And then folks with stroke often have disturbance to their sleep and may develop insomnia after experiencing a stroke. So those are specific populations where I think the yield is high to be looking for insomnia and other sleep disorders. Dr Grouse: Yeah, that makes sense. I think a lot of us think of insomnia as almost like, make sure we're not missing this as sort of a mimic of the problem, when in fact it's probably just more part and parcel of the problem and something we need to be thinking about treating as part of their disorder. So helpful to think about it in that light, at least in my own mind. Now, I want to get a little bit back to some of the therapies you've recommended, and I think first just stopping again at sleep hygiene. Your article has a really great list, I think, of sort of like a checklist of actions that people should be taking to make sure that they are managing their sleep hygiene well. And I definitely recommend our listeners look to that. How often do you think that focusing on sleep hygiene helps when you get a patient who says, "Hey, I have got terrible sleep. You know, what do I do?" Dr Peters-Mathews: It's pretty common for people to have access to this information through their own reading online, and most folks have worked through this by the time they've come to see me, and often a primary care provider or specialist may have given some of this guidance as well. It's pretty rare for them to not recognize something as obvious as having caffeine too late in the day by the time they're coming to my attention. The sleep hygiene generally is used as a control when we do research to look at how something like medication is working or CBT-I might be working. It's the comparative control. It's almost like the null intervention. So, it's not highly effective, and if folks are not finding it helpful, they've made those adjustments to their sleep environment or their habits, and they're continuing to have issues, there's typically more that needs to be done, and that's where CBT-I really comes in as a strong intervention for those people. Dr Grouse: And then getting on the topic of CBT-I, so helpful. I'm really glad that your article spent a lot of time talking about it as really a truly high-yield, great intervention for insomnia. And I really felt that the question shouldn't be: When is cognitive behavior therapy for insomnia helpful? But like, when isn't it helpful? What are your thoughts about that? Dr Peters-Mathews: Yeah. I always point out that the American College of Physicians has recommended CBT-I for adult patients as the initial treatment for chronic insomnia even before the use of a medication for nearly ten years. That recommendation came out in July of 2016. So, there are folks who may not be good candidates for it, who may be screened out because of other conditions that they have, and there certainly are folks who don't do as well with CBT-I. And adherence is important. Somebody needs to be able to follow the instructions and apply that to their lives. And certainly, there are a number of things that could interfere with that compliance. I would say untreated anxiety and pain are two things that often trip people up. It's like running a race with a broken leg. Despite their best efforts, if those are not addressed, they will continue to have issues around insomnia. And then one thing that often is unrecognized and may be missed is untreated sleep apnea. That is a common contributor to a chronic insomnia, especially in older folks, women beyond the age of menopause and men even starting in middle age, thirties and forties. We don't want to miss sleep apnea. Even insomnia that's, "I can't fall asleep at the beginning of night," that could still be sleep apnea, so that's something I really emphasize with my patients. Dr Grouse: Really great reminder about sleep apnea for sure. Something that always is beneficial to make sure we are not missing. Oftentimes I'll bring up a CBT for insomnia, and what is that? Like, what would we actually do, and what is a high-level overview of what happens with CBT-I? Dr Peters-Mathews: Yeah. So, I generally tell my patients that this is a six-week program. It's a structured program, almost like a boot camp for sleep, in which we are addressing underlying causes, recognizing what those are and, and working through those underlying causes. There is often tracking using a sleep log or sometimes wearable data.To guide decisions that are made in the program. It's very goal-directed, science-based therapy. We often introduce concepts around sleep drive, circadian rhythm dealing with a busy mind at night. There's concepts of mindfulness and relaxation training that are introduced. People often are able to taper or stop using sleeping pills as part of this therapy. And the nice thing is they walk away with a set of skills that they can apply the rest of their lives to sleep more normally. And so, there's good research that suggests even years after someone's completed a CBT-I course, they continue to sleep more normally. They have the tools that they need to sleep better even years beyond that education. Dr Grouse: You know, this just sounds so great. It almost sounds like why wouldn't someone benefit from this? But of course, like I would imagine many institutions experience, I've definitely run into difficulties with access for my patients for CBT-I, and we have long wait lists. And I imagine there's many places where there just aren't even any specialists that patients can get to, to help with this. What are the resources that our listeners can take advantage of for their patients to get access to these types of therapies? Dr Peters-Mathews: So, one thing I tried to really emphasize in the article is that there are resources that can be drawn in. I'll give you some examples. So, at our institution, we have three sleep specialists, full-time sleep specialists, who trained at Stanford to become CBT-I specialists, and so we have more resources than probably most institutions would have. We do shared medical appointment workshops so that we can manage the number of patients that we have to see. And, and unfortunately, not everybody has that opportunity. You might plug into resources in your community, and one of the resources I point to in the article is the International Directory that's managed by the University of Pennsylvania that has eight hundred and seventy-five CBT-I specialists listed with contact information, et cetera. And I think that's an amazing opportunity to access this therapy. Unfortunately, there are countries and certainly states that do not have a specialist, that there's no one in the state that provides this therapy. And then we need to extend other resources, and that could be online treatment programs that can be done independently, bibliotherapy, so accessing books that could guide people through the therapy, even accessing other apps and maybe even wearables that pair with an app that could provide some of this guidance. The Veterans Administration worked with Stanford and worked with the National Center for PTSD and developed an app called CBT-I Coach that is free and can be downloaded and, and gives, I think, good education, good guidance. So, there are resources that exist. It's somewhat finding what might work for your individual patient, how they're preferring to access this or their learning preferences. Do they want to read a book or not? And getting them into the right pathway. Dr Grouse: And I think that gets me into a whole other Pandora's box of the fact that they're already out there in the world are tons of different apps, wearable devices, all sorts of things that promise that they can help us with sleep, some that may have more, I think, data and evidence behind them than others. Do any of these apps or wearables in your mind show promise in our patients helping our patients track and diagnose and manage their insomnia? Dr Peters-Mathews: Yeah, there's a lot out there, and unfortunately, some of these devices actually can make sleep worse. People can develop a condition called orthosomnia or straight sleep, where they're trying to perfect their sleep and their sleep numbers, their metrics, and the wearables feeding them data that they continue to try to improve upon. And that fixation on those metrics can actually make their sleep quite a bit worse. A lot of these wearables and apps and other resources have not been well-studied. There's not research trials showing outcomes comparing to other standards of care. I would say the basic guidance of CBT-I, which many of these programs are based on, I think will be helpful to the majority of folks who are able to engage and complete that education. A lot of these are not dependent on that sort of framework or structure so that we may not actually be using the standards of CBT-I to try to improve sleep. They may be connecting you with other resources, like listen to this sleep story or this relaxation file or do some meditation, et cetera, which again, may be of some benefit, but it is not the same as a structured CBT-I experience. So, I think there are a few good resources that we highlight within the article, and I think there are probably others coming that may give individuals a more individualized, directed approach to managing their sleep issues. But it's almost like going to the App Store and there's thousands of apps. It's hard to know which one might be most based on science or the most beneficial to that individual. Dr Grouse: Well, I really appreciate in your article that you did have a great list of apps and things along those lines to try, so I do encourage our listeners to check that out as well. Some really, really great resources there in the article in many different areas. Now, I wanted to turn the conversation to a slightly different thing, which is medications for insomnia. Now, when are medications appropriate for treating insomnia? When should we be thinking about turning to these for our patients? Dr Peters-Mathews: So again, we would suggest that CBT-I would be first, and that failing improvement with CBT-I, that medications would be extended to a person affected by insomnia. And over-the-counter options as well as prescription medications might be used. Unfortunately, that's not how things unfold in the real world. Many people are jumping to medications first, whether that be an over-the-counter supplement or other medication, or they're seeing primary care and other specialists who's providing them a prescription for sleep aid. So there's data from the CDC going back to twenty twenty that suggests that about six point three percent of adults were taking a sleeping medication every day in the months prior to the survey. And women who were older than sixty five, white women, were more likely to be using a sleeping medication every day. That number was 13.5 percent of those surveyed. So, lots of folks are on medications, and certainly melatonin is widely used. Unfortunately, it's not regulated by the FDA in a sense that we don't have exact concentrations controlled. So, people can take melatonin that has no melatonin in it. They might take melatonin that's forty or more times the dose. There's variance within lots from the same manufacturer. There's a lot of trouble knowing exactly what you're getting when you try to take something like melatonin over the counter. Other sleep aids that we might reach to over the counter, like variants of diphenhydramine or doxylamine, and these are often the PM drugs that we think about. They have risks associated with population-based studies which suggest risk of dementia, risk of falling, risk of mortality with these drugs, especially in older populations. So again, that would give us potentially pause. The prescription medications that we go to, there are some that the American Academy of Sleep Medicine would recommend as more beneficial than harmful, and some are good for both initiating and maintaining sleep. Some have such a short half-life that they're really best as initiation drugs. And then others are better for maintenance of sleep, so reducing awakenings and wakefulness in the night. My own individual take, often people are coming to me on medications, typically over the counter, but often prescriptions, and have even tried and failed many of those medications before they finally come to see a specialist. And so, I don't often reach to medications until I've exhausted CBT-I, until we've completed a sleep test to make sure we're not missing something like sleep apnea, until we've ruled out some other potential contributing causes. But there are patients I have who really will not sleep without medication support and sometimes even multiple medications that work in complementary ways to try to normalize their sleep. And so, in some cases it is necessary, but it is not meant to be a first line for anyone. Dr Grouse: Yeah, and I think all of our listeners can relate to the fact that we often see patients who've been on sleep medicines for many, many years and take them every night. It's good to know that there is sort of a procedure here to consider and perhaps again, back to the plug to CBT-I as being the right starting point to see if there's some that we can help get off of these meds, although, as you mentioned, maybe not always going to be successful. Well, I really appreciate our conversation about this. It's been really great to read this article about insomnia. Again, I encourage our listeners to check it out. Some really great resources for many different therapies, thinking about other alternative diagnoses and different medical conditions where insomnia really needs to be considered. And I really appreciate you writing this article. It's been a pleasure to talk with you today. Dr Peters-Mathews: It's my pleasure to share this information with folks, and I hope that you find it useful in your clinical practice or even your personal life as the need arises. Dr Grouse: Again today, I've been interviewing Dr. Brandon Peters-Mathews about his article on insomnia. This article appears in the August 2026 Continuum issue on Neurology of Sleep. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today. Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audiocme. Thank you for listening to Continuum Audio.
For a long time, video games and brain health existed in completely separate conversations. Games were entertainment — a guilty pleasure at best, a concern at worst. That is changing. And the science behind that change is more compelling than most people realize.In this episode Dr. Krystal Culler and co-host Dr. Jonathan Artz, MD sit down with Dr. Julia Scott, Ph.D. — neuroscientist, researcher, and co-founder of Gambit Labs — to explore video games and wearable sensors as genuine tools for brain health. Not as a replacement for the fundamentals, but as a powerful and increasingly accessible addition to our brain care toolkit — one that can reveal things about our brains we have never been able to see before.What You'll Learn in This Episode
The Lindsay Clancy jury continues deliberating as reports of two jurors wearing pink raise new questions about impartiality - The MK True Crime Show's Dave Aronberg weighs in. Flash flooding in the Grand Canyon leaves at least two people dead, many more missing, and destroys critical bridges and water infrastructure. New reporting details turmoil inside the Pentagon, including Dan Driscoll's reported resignation and warnings about the strain of operations against Iran. The FDA approves a new once-daily pill for metastatic pancreatic cancer after trial results showed patients living nearly twice as long as those receiving chemotherapy. Cozy Earth: Visit https://www.CozyEarth.com & Use code MEGYNAM for up to 20% off Lean: Discover why LEAN is becoming the choice for real weight‑loss results—shop now at https://TAKELEAN.com use code MK. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Venezuela makes a once-unimaginable turn toward American oil investment, privacy advocates propose “collective bargaining” for personal data, and Trump's FDA nominee inherits a long-stalled review of the abortion pill. Plus: Where religion becomes rule, Cal Thomas on the test that caught his cancer, a Vermont woman growing a dress so slowly the fashion trend may come back around, and the Tuesday morning news.Support The World and Everything in It today at wng.org/donate.Additional support comes from Cedarville University—a Christ-centered, academically rigorous university located in southwest Ohio, equipping students for Gospel impact across every career and calling. Cedarville integrates a biblical worldview into every course in the more than 175 undergraduate and graduate programs students choose from. New online undergraduate degrees through Cedarville Online offer flexible and affordable education grounded in a strong Christian community that fosters both faith and learning. Learn more at cedarville.edu, and explore online programs at cedarville.edu/online.From World Watch. A 10-minute daily news program that explores current events for students 5-12th grade. This high-energy show connects learners to the present, history and communities around the world. Join 40,000 Christian families that utilize World Watch as a tool to foster curiosity and have conversations about today's news as a discipleship rhythm within their families. “Whatever the news, the purpose of the Lord will stand!” First time? Take advantage of a 30-days free trial at worldwatch.news/podcast. Not ready to sign up? Check out a free episode at get.worldwatch.news/free-episode. And from Boyce College—which offers a Christ-centered education built on the truth of God's Word. Every student—no matter their major—takes 30 hours of Bible and theology, learning how to think biblically, live faithfully, and lead with conviction.Formed from the 160-year legacy of Southern Seminary, Boyce College prepares students for maximum faithfulness in the world, the workplace, the church, and the family.Learn more at boycecollege.com
CONTENT WARNING: Reggie Watts' recent accusations But first, FDA, USS Abraham Lincoln, ICE shock gloves, indigestion, and more. Subscribe to our bonus feed for the full ep and more: Patreon.com/poddamnamerica
The Nurses Report on America Out Loud with Gail Macrae, BSN, RN – That system is four agencies working in concert. NIH funds the papers that supply the narrative. CDC turns the narrative into recommendations. CMS attaches the money. FDA supplies the EUA that makes the whole chain legally possible. It is a network. Subpoena power exists to pull the records those agencies already...
On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more... Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Welcome to September! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved – more on that coming up. But please register – the link is in the show notes. So much going on over here – tomorrow night we have our Club 1921 in Charlotte, later this month Moms' Night Out Detroit/Bloomfield and in October we're going to Seattle. Please join us. More at d-c dot com slash events. Okay.. our top story this week: XX Another indication for Mounjaro – the FDA approved it to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro – the brand name of tirzepatide - is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. The approval was based on results from the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide). https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html XX The FDA approves the Libre Duo – the first device designed to continuously monitor both blood sugar levels and ketone levels in people with diabetes. The Libre Duo 10-Day Continuous Dual Glucose Ketone Monitoring System is now approved for those ages 2 and older. Until now, the agency said, people had to monitor ketone levels with separate tests that only provided a single measurement at one point in time. The new system combines blood sugar and ketone tests and monitors them continuously. Readings -- and alerts in case of dangerous trends -- are sent wirelessly to a smartphone app. The FDA previously granted "breakthrough device" status to the system, which is meant to expedite the device's development and review. https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/ XX Diabetes tech firms Dexcom and Abbott are watching closely for a Medicare coverage expansion that could significantly broaden access to their glucose sensors. The Centers for Medicare and Medicaid Services is expected to expand Medicare coverage of continuous glucose monitors to people with diabetes who do not take insulin. Currently, coverage is limited to people with Type 1 or Type 2 diabetes who take insulin or have a history of problematic low blood sugar. Dexcom CEO Jake Leach told investors in a late July earnings call that the company expects to hear back from the CMS before the end of the year, with coverage going into effect in mid-2027. Dexcom presented results of a randomized, controlled trial earlier this summer at the American Diabetes Association's Scientific Sessions that it expects will support the CMS' decision. The 26-week study found that people who used a CGM had a larger hemoglobin A1C reduction than the control group and spent five more hours per day in a normal glucose range than the control group. https://www.medtechdive.com/news/dexcom-abbott-await-medicare-coverage-expansion-for-cgms/828775/ XX A new study suggests continuous glucose monitors (CGMs) may offer benefits for people with type 1 diabetes that go beyond improving blood sugar and reducing hypoglycemia. Researchers analyzed health records from more than 8,400 adults with type 1 diabetes receiving care through the Veterans Health Administration. Over one to four years of follow-up, people who started using a CGM had a 10% to 16% lower risk of death from any cause compared with those who did not use one. The association appeared strongest among people over age 65 and those who were not using insulin pumps. Researchers did not find meaningful differences based on A1C, race or ethnicity, or frailty. Importantly, this was an observational study using medical records, not a randomized clinical trial, so it cannot prove that CGM use directly caused the lower death rate. But the findings suggest CGM may have important long-term health benefits beyond glucose management.https://visualize.jove.com/42319755-continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-onset-type-1-diabetes-patients-a-target-trial-emulation-study-within-the-veterans-health-administration XX We've been talking about people without diabetes using CGMs for a long time.. now a new study weighs in. Research published in JAMA finds that this wellness trend isn't helpful for people without a diabetes diagnosis. They found that the strongest evidence for CGM use is for people who are already living with diabetes, but not for those without the condition who use them for wellness purposes. It's also worth noting, though, that this new study is a narrative review. This means that the researchers drew their conclusions from the findings reported in several other studies. More randomized controlled trials would be necessary to see whether there are any meaningful health benefits of using a CGM if you don't have diabetes. Dower also warned that constantly monitoring your blood sugar when you don't have diabetes could lead to unintended health anxiety. In some cases, you may even make accidental lifestyle changes that could be harmful. "[Blood sugar] spikes may occur after meals, but if this leads someone to replace healthy food such as fruit with unhealthy food such as something high in fat but low in carbohydrate, the glucose information has done more harm than good," Dower said. https://www.verywellhealth.com/blood-sugar-monitor-for-people-without-diabetes-12058575 XX Could metformin somehow influence the biological processes that drive aging? A new review found evidence that metformin may affect several key features of aging, including how cells use energy, inflammation, cellular damage and even some changes in gene activity. Animal studies have shown longer lifespans or improvements in markers of biological aging, while some human studies have also found promising results. But researchers say there's still no proof that metformin actually slows aging or helps healthy people live longer. Most human research has involved people with diabetes or other health conditions, and one large trial found that while metformin helped prevent type 2 diabetes, it did not reduce cancer, cardiovascular disease or deaths. Researchers say larger clinical trials in people without diabetes are needed to determine whether metformin can truly extend healthy lifespan—or whether its benefits are primarily related to preventing and treating specific diseases. https://www.technologynetworks.com/drug-discovery/news/metformin-may-influence-longevity-through-the-gut-microbiome-and-epigenetic-changes-416035 XX More to come including more research on a spice thought to help diabetes, predictions about the number of people who may be living with type 1 in the years to come around the world, and a connection I didn't know about between diabetes and Dolly Parton. XX A compound found in turmeric may help protect blood vessels from some of the damage caused by Type 1 diabetes. In rats, curcumin reduced inflammation, improved cellular signaling, and restored vascular health to levels resembling those of nondiabetic animals. The results hint at a possible new way to reduce the long-term cardiovascular risks of diabetes, but human trials are still needed. Curcumin, the natural compound responsible for turmeric's vivid yellow color, is widely studied for its anti-inflammatory and antioxidant properties. https://www.sciencedaily.com/releases/2026/08/260824065543.htm XX New research estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049. This will be presented at EASD, the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2 The USA will see an increase of over half a million, going from 1,492,825 to 2,055,235. The authors suggest that the reasons for the predicted high incidence and prevalence in 2049 in countries such as Australia, US, UK are likely to be a combination of genetics, environmental triggers and also high case detection rates (due to the good health care infrastructure here and in other HIC). Unlike previous estimates, the DIAMOND-T1D model takes historical patterns of insulin availability into account and aims to provide global, regional and country-specific estimates of T1D incidence, prevalence and mortality from 1900 to 2050. Although the majority of people with T1D live in high-income countries (HIC) and middle-income countries (MIC), the largest relative increase in the T1D prevalence is expected to occur in LIC as access to insulin, glucose monitoring and survival all improve in those countries. https://www.news-medical.net/news/20260828/Type-1-diabetes-cases-projected-to-increase-worldwide-by-2049.aspx XX Early initiation of statins after a diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study published in The Lancet Regional Health – Europe. According to the Lancet Commission, nearly half of dementia cases could theoretically be prevented by eliminating 14 risk factors. "Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor," From Danish registers, researchers identified 132,585 statin-naive individuals who developed type 2 diabetes from 2006 through 2019, with follow-up until the end of 2021. Medical records were searched for diagnoses of all-cause dementia. A clone-censor-weight design was used to analyze dementia incidence in patients with no statin initiation within five years after diagnosis, in those with early statin initiation within one year and in those with late statin initiation between one and five years after diagnosis. https://medicalxpress.com/news/2026-08-early-statins-diagnosis-diabetes-dementia.html XX We are heartbroken over the loss of our friend Dolly Parton. Dolly was a beloved icon whose extraordinary generosity, warmth, and compassion touched countless lives, including those of the Children's Diabetes Foundation and the Barbara Davis Center for Diabetes. Her support of The Carousel Ball and Carousel of Hope Ball reflected her deep commitment to helping children and families affected by type 1 diabetes. Beyond her remarkable talent, Dolly will be remembered for the kindness and joy she shared so generously with others. Our hearts are with her family, friends, and all who loved her as we celebrate her extraordinary life and lasting legacy. She will be deeply missed.
August 2026 will be remembered as the month the institutions finally caught up to the warriors who went first. In this episode, Whiz Buckley walks through thirty days that would have been unthinkable five years ago. The VA Secretary reported his department is making real strides on psychedelic therapy for veterans. The Department of War formally recognized Operator Syndrome — the cumulative toll carried by the men and women who spent careers at the tip of the spear. The New York Times ran a piece on Americans facing danger seeking treatment at clinics outside the country. And hours later, a federal report from SAMHSA landed telling states to start preparing now for FDA approval of psychedelics — the clearest signal yet that this is no longer a question of if.Whiz also connects a thread most people missed. A year and a half ago he sat down with VA Secretary Doug Collins and told him to go get the ibogaine research Dr. Deborah Mash had done in the early 1990s — work that had been sitting on a shelf for three decades. This month, the President announced the University of Miami had handed that entire investigational drug application over to the federal government.He closes where the whole thing started. Five years ago he was lying on a mattress in Mexico. This year he stood in the Oval Office for an executive order signing. No one is ever truly broken — God does not make imperfect things — and August proved the machine is finally moving.Fight's On!
In this Diving Deep episode, Dr. Robert Pearl and Jeremy Corr examine two very different healthcare debates that share a common problem: when medicine lacks good evidence and aligned incentives, patients and doctors are left with bad choices. The conversation begins with experimental peptides, a fast-growing topic on social media and in wellness circles. Dr. Pearl reviews the FDA's ongoing debate over whether six experimental peptides should be made available to licensed compounding pharmacies. Supporters argue that Americans are already buying these substances through the gray market, often from overseas suppliers, and that regulated access would be safer. Critics argue that expanded access would encourage far more people to use products whose benefits, risks, purity and long-term safety remain uncertain. For Pearl, both sides are partly right, which is why a simple yes or no is the wrong answer. Saying no would not eliminate demand. It would leave many Americans buying peptides online without reliable quality control. Saying yes without conditions would create the impression of FDA approval without the scientific evidence normally required to prove safety and efficacy. Instead, Pearl argues for a third path: pair regulated access with federally coordinated research, safety reporting and controlled studies so patients, doctors and regulators can learn whether these peptides actually work and whether they are safe. The second half of the episode turns to primary care, a specialty Pearl says is in serious trouble. Primary care physicians are overburdened, under-resourced and underpaid compared with specialists. They face growing patient panels, administrative demands, declining autonomy and less interest from medical students entering the field. Pearl acknowledges that primary care leaders are right to ask for more respect, more support and better compensation. But he argues that payers are unlikely to invest substantially more unless primary care can demonstrate better outcomes and lower total costs. That has not happened consistently under traditional fee-for-service or pay-for-performance programs, which reward isolated steps in care rather than overall clinical impact. The solution is capitation. Under this model, primary care doctors would receive a prospective payment to care for a defined population rather than being paid for each visit or service. If chronic diseases are controlled, emergency department use falls and complications decline, both patients and clinicians benefit. But capitation also requires doctors to accept financial risk, organize into larger groups, adopt common clinical standards, coordinate care and empower effective physician leaders. The episode closes with a call for national primary care societies to lead. Pearl says they can help doctors form groups, negotiate capitated contracts, purchase stop-loss protection, implement generative AI, build clinical infrastructure and spread best practices from early demonstration programs. Across both topics, Pearl returns to the same point. Whether the issue is experimental peptides or the future of primary care, patients need evidence, doctors need accountability and the system needs incentives that reward better health. For more, tune into this month's episode and check out the link below. Helpful links: The Best FDA Decision On Peptide Authorization Isn't Yes Or No (Forbes) Monthly Musings on American Healthcare (RobertPearlMD.com) * * * Dr. Robert Pearl is the author of ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine. Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post FHC #226: Peptides, primary care & the false choices in American medicine appeared first on Fixing Healthcare.
Send us Fan MailEPISODE DESCRIPTION - Ready to publishRhode Islanders are sending a blunt message: the healthcare system is not just expensive, it's forcing people to delay care, skip tests, and rethink whether treatment is even worth it. University of Rhode Island sociologist Julie Keller unpacks the new survey data exposing how deep the affordability crisis really goes - and why the numbers are more alarming than the anecdotes.The findings go beyond general frustration. 29% of respondents say they delayed medical care in the last year because of cost, and among those postponing recommended care, cost is the biggest reason. Keller explains why the wording of these questions matters, how the survey captures the difference between general concern and real-world barriers, and why that gap is so consequential for health outcomes and medical debt.We also break down the broader public sentiment shaping Rhode Island right now: 72% worry about healthcare costs 72% also worry about housing costs 93% trust their own doctor Trust drops sharply for institutions like the CDC, FDA, Rhode Island state officials, RFK Jr., and Trump 49% say they use AI for health information, raising new questions about how people search for care and advice Keller also shares what Rhode Islanders say they would support to fix the system, including a URI medical school, loan forgiveness for doctors who stay in the state, and higher Medicaid reimbursements. If you're trying to understand why healthcare keeps rising to the top of Rhode Island's political agenda, or what kinds of solutions actually have public support, this episode gives you the clearest picture yet.Essential listening if you care about healthcare costs, access to care, policy reform, or the real state of public opinion in Rhode Island right now.Support the showFollow Bill on Instagram and YouTube
With no FDA-approved therapies for Sjögren's disease, how can ENTs and allergists provide effective care and keep up with emerging treatments? On this episode of BackTable ENT & Allergy, Dr. Basil Kahwash interviews Dr. Kara Wada, a Columbus-based allergist, immunologist, and lifestyle medicine physician, about her personal and clinical experience with Sjögren's disease. They discuss the major gaps in current treatment, the evolving role of otolaryngologists and allergists in multidisciplinary care, and the new therapies on the horizon. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:21 - Building A Direct Practice04:24 - Personal Sjogren's Diagnosis08:33 - ENT Presentations11:28 - Biopsy Challenges and Seronegative Disease15:48 - Pulmonary Complications17:55 - Clinical Trial Treatment19:47 - Immunology and Disease Mechanisms25:35 - Lab Workup and Risk Assessment29:32 - Overlooked Symptoms and Nutritional Considerations31:51 - Saliva Stimulants Tradeoffs34:42 - Deciding When to Escalate Systemic Therapy35:51 - Hydroxychloroquine Basics38:26 - Multidisciplinary Dream Team41:45 - Rituximab and IVIG44:35 - Investigating Phase Three Therapies47:23 - Path to Becoming a Sjogrens Expert53:33 - Key Takeaways And Resources --- More about this episode Dr. Wada details her own diagnosis and the complex presentations of Sjögren's across ENT subspecialties, including dry eyes, nasal and throat tissues, chronic sinus issues, laryngitis, reflux, salivary gland swelling, neuropathy, and dizziness. The conversation covers diagnostic workup, the importance of lip biopsy and expert pathology, the challenges of seronegative and pulmonary cases, and the limitations of current medications like hydroxychloroquine and rituximab. They also discuss ongoing clinical trials, dryness management, overlooked symptoms, and the emerging role of agents such as inalumab and dazedalimab in late-phase studies. --- Resources Virtual Sjögren's Summithttps://www.sjogrenssummit.com/ --- BackTable ENT & Allergy is the go-to podcast for otolaryngologists, allergists, and head and neck surgeons. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about studies that are being done to slow the progression of Alzheimer’s disease, the FDA approving a drug treatment for pancreatic cancer, and what we know about this year’s flu season.
What could a major change to the GRAS framework mean for food companies? In this episode, we unpack the FDA's proposed rule that would transform the long-standing voluntary GRAS notification system into a mandatory one, while also expanding the scope of the program and creating a streamlined pathway for certain substances already on the market. We explore what the proposal could mean for companies relying on self-affirmed GRAS determinations, including new notification requirements, transition periods, potential post-market scrutiny, and longer FDA review timelines. The proposal also raises significant questions about FDA's legal authority and whether the agency has the resources to manage a substantial increase in submissions. For food and ingredient companies, the rule could represent one of the most significant changes to the GRAS framework in decades, making it important to assess current GRAS determinations and prepare for what comes next. Hosted by Simone Roach. Based on a blog post by Donnelly L. McDowell, Katie Rogers, and Cristina Ferretti.
Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trade-offs companies face, the litigation risks around mandatory Medicare MFN pricing demonstrations, and what happens to companies that don't sign on.The analysts also discuss Eli Lilly's acquisition of Merida, its thirteenth takeout of the year, Heidi Overton's nomination as FDA commissioner and what it signals about FDA independence, and Revolution Medicines' 35-day filing-to-approval timeline under FDA's national priority review voucher pilot.View full story: https://www.biocentury.com/article/660655#DrugPricing #FDA #BiotechMA #Oncology #BiopharmaPolicy0:00 - Introduction2:14 - MFN Drug Pricing Deals10:09 - Lilly Acquires Merida22:22 - FDA Commissioner Pick30:11 - RevMed's Rapid ApprovalTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Clinical Disclaimer: This episode is for educational purposes for licensed healthcare professionals and is not individual medical advice. Ketamine and esketamine are not FDA‑approved for preventing or treating postpartum depression; any use in this population is off‑label and should be considered investigational and undertaken only with appropriate training, collaboration, and adherence to current standards of care.Postpartum depression affects roughly 10 to 20 percent of mothers and remains one of the most undertreated conditions in medicine. As public awareness of maternal mental health grows, providers in the ketamine and psychedelic therapy space are increasingly asking: is there a role for ketamine or esketamine here?This episode is our evidence-based answer to that question.We walk through the current clinical literature on ketamine and esketamine for perinatal depression, drawing on randomized controlled trials, meta-analyses, and expert commentary from institutions including the Center for Women's Mental Health at Massachusetts General Hospital. The research landscape is more nuanced than most providers realize, and understanding it clearly matters both for patient conversations and for how you think about your practice's scope.One distinction shapes everything that follows in this episode, and it's an important one: virtually all of the existing trial data involves perioperative prevention in cesarean delivery populations, not outpatient treatment of established postpartum depression. Knowing what the evidence actually supports and where the gaps remain is essential context for any provider working in this space.What You'll Gain· A clear breakdown of what current ketamine and esketamine trials actually show for postpartum depression prevention, and what limited data exist for treatment.· An understanding of why racemic ketamine and esketamine tell different stories in the peripartum literature.· The key ethical and practical considerations for any provider thinking about this population.· An honest framework for how to talk with patients who ask about ketamine for postpartum depression.· Context on what the research gaps mean for where this field is heading.Review the research behind this episode, including full citations for every study discussed, in the Clinical References and Further Reading.
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about studies that are being done to slow the progression of Alzheimer’s disease, the FDA approving a drug treatment for pancreatic cancer, and what we know about this year’s flu season.
Why are men encouraged to monitor their testosterone levels while women are often told not to bother checking theirs? On this episode of Redefining Medicine, OB/GYN Dr. Tara Scott, MD, takes on the double standard surrounding testosterone treatment for women and why it's time for the conversation to change. From cognition and mood to libido and vaginal health, testosterone can play an important role in women's health. Yet women often face significant barriers when it comes to testing, treatment, and access to appropriate dosing. Dr. Scott explores the history of testosterone research for women, including a promising 300-microgram patch that never received FDA approval despite positive data and no major safety concerns identified in the research discussed. So, what needs to change? Dr. Scott dives into the knowledge gap surrounding testosterone in women's health and the importance of helping more OB/GYNs gain the education and confidence to appropriately evaluate and address their patients' hormone needs. Could greater education and research finally help close the gap in women's hormone care? Tune in for a thought-provoking conversation that challenges the status quo and asks why women are still being left out of the testosterone conversation.
Shop my all-natural skincare products at Arvoti.com.The man who invented the cloudbuster died in a federal prison, and his research was burned, ordered by a US court.His name was Wilhelm Reich, a physician and psychoanalyst who spent decades studying what he called orgone energy, a force he believed moved through living things and the atmosphere.Reich designed arrays of hollow metal pipes connected to water and pointed them at the sky. He claimed they could shift atmospheric conditions, dissipate clouds, and even bring rain. In 1953, blueberry growers in Maine paid him after rain followed one of his experiments. In the mid-1950s, he ran the same tests in the Arizona desert.Then the FDA came for his orgone accumulators, a federal court issued an injunction, and quantities of his publications were destroyed under court order. He died in prison in 1957.I've been running my own backyard version of his work. Copper pipes in the garden. A gravel basin with water. Blackberries and strawberries responding on the copper side. Skies clearing after wildfire smoke. And posts about it getting flagged and hidden online.If copper in a garden is harmless nonsense, why work so hard to make sure people don't hear about it? That's what this one is really about.You'll Learn:[0:00] Introduction[3:24] Copper in the garden and getting community noted[5:46] Orgone energy and why modern physics rejects it[9:43] Deadly orgone radiation and cosmic orgone engineering[13:29] Why copper became the material of choice for builders[15:03] The FDA injunction and burning of Reich's publications[17:53] Reasons someone might want the cloud buster information gone[20:36] What homesteading teaches about trusting your own observations Resources Mentioned:Cloudbuster | WikipediaThe Development of Orgonomy, Wilhelm Reich | WebsiteFind more from Gubba:Gubba Homestead | X | Facebook | Instagram | Pinterest | WebsiteGubba Homestead Products | Shop
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about studies that are being done to slow the progression of Alzheimer’s disease, the FDA approving a drug treatment for pancreatic cancer, and what we know about this year’s flu season.
From Washington, D.C., Richard joins OANN's John Hines to expose the mysteries, conspiracies and hidden history behind Tales from the Rock & Roll Twilight Zone. FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet SUPPORT OUR SPONSORS!!! HIMS Weight Loss By HIMS -HIMS now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy® pill and the Wegovy® pen. Ready to reach your goals? Visit hims.com/strangeplanet to get a personalized, affordable plan that gets you. MARS MEN Mars Men helps you reclaim your edge with natural testosterone support for energy, focus, and strength Go to MenGoToMars.com right now, for a limited time, listeners of this program get 50% off for life, plus free shipping AND 3 free gifts. QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. CARGURUS CarGurus is the #1 rated car shopping app in Canada on the Apple App and Google Play store. They've got hundreds of thousands of cars from top-rated dealers, plus advanced search tools that let you zero in on exactly what you want. And you can set real-time alerts for price drops and new listings — so you never miss a great deal. Buy your next car today with CarGurus at cargurus dot ca. Go to cargurus dot ca to make sure your big deal is the best deal. BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit https://strangeplanet.supportingcast.fm Use the discount code "Planet" to receive $5 OFF any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/
Researchers found that Wegovy showed the strongest reported association with a rare optic nerve injury that can cause sudden vision loss, raising new questions about the safety of high-dose semaglutide formulations Men using Wegovy showed the highest reported risk in the FDA safety database, with odds of optic nerve injury appearing substantially higher than those reported for women Analysis of more than 400,000 online discussions revealed that many GLP-1 users frequently reported fatigue, low energy, menstrual changes, chills and hot flashes — symptoms that receive far less attention than digestive side effects Real-world patient conversations and artificial intelligence analysis are helping researchers identify emerging drug safety signals much faster than conventional reporting systems alone Your body already produces its own GLP-1 hormone through gut microbes that generate butyrate, and restoring this natural system through better gut health supports appetite control and metabolic function without relying on injections
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with psychiatrist and TaperClinic founder Dr. Josef Witt-Doerring about antidepressant withdrawal, psychiatric deprescribing, and psychedelic readiness. Find full show notes and links here: https://thethirdwave.co/podcast/episode-371/?ref=278 Josef explains what he learned reviewing drug safety at the FDA, why withdrawal can be mistaken for relapse, and how tapering often becomes more difficult at lower doses. They also explore the lifestyle foundations of mental health, benzodiazepine withdrawal, and why psychedelic clinics may need far more sophisticated support as increasingly medicated patients seek psilocybin, MDMA, LSD, and ketamine. Dr. Josef Witt-Doerring, MD, is a psychiatrist renowned for his expertise in drug tapering and withdrawal management. With years of experience in clinical psychiatry, he has developed a particular interest and specialization in assisting patients with the safe and effective tapering of psychiatric medications. His approach is patient-centered, focusing on individualized plans that prioritize patient well-being and functioning. He is the founder and medical director of TaperClinic. Highlights: What antidepressant research leaves unanswered Why withdrawal can resemble relapse How lower doses change tapering Five foundations before optimization hacks Benzodiazepines in psychiatric deprescribing Psychedelics versus conventional drug models Insurance pressure on psychedelic clinics Preparing for heavily medicated patients TaperClinic: https://taperclinic.com/ TaperClinic Free Guide: https://taperclinic.com/free-guide/ SSRI Deprescribing & Psychedelic Readiness Training with Dr. Dave Rabin: https://edu.psychedeliccoaching.institute/ssri-deprescribing-and-psychedelic-readiness-certification/?ref=12 Disclaimer: This content is for educational, informational, and entertainment purposes only. We do not promote or encourage the illegal use of any controlled substances. Nothing said here is medical or legal advice. Always consult a qualified medical or mental health professional before making decisions related to your health. The views expressed herein belong to the speaker alone, and do not reflect the views of any other person, company, or organization.
Dr. Rachel Rubin is changing the landscape of women's health—and she's not waiting around for permission.In this fiery conversation, we talk about why sexual medicine has been ignored for so long, the massive education gap around menopause and hormones, and Rachel's work fighting to remove the FDA boxed warning from vaginal estrogen.We also get into why pelvic PTs and OTs need to own our role in recognizing hormonal and vulvar changes, why the future of women's healthcare requires a multidisciplinary “pit crew,” and Rachel's philosophy that no grown-ups are coming to save the day.Plus, we talk disruption, entrepreneurship, taking action, dealing with criticism…and why Rachel believes pelvic rehab providers are becoming leaders in this space.About Dr. Rachel RubinDr. Rachel Rubin is a board-certified urologist and sexual medicine specialist, nationally recognized for her work in women's sexual health, menopause, hormones, and Genitourinary Syndrome of Menopause (GSM).Learn more from Rachel at Dr. Rachel Rubin's website and follow her on Instagram @drrachelrubin.See Rachel at PelviCon!Rachel is making PelviCon history as our first physician speaker!She'll be delivering her keynote on Disrupting the FDA: A Fight for Vaginal Estrogen Safety AND a four-hour Pre-Con deep dive on Vulvar Exams for Pelvic Therapists.Join us for PelviCon Live Virtual + Recording and get lifetime access to Rachel's keynote and all of the incredible PelviCon content.Get PelviCon Live Virtual + Recording →About Nicole & Jesse CozeanPelvic health is hard. We want everyone in this field to have a joyful, impactful career—and for business owners to build something that truly works for them.
It's our monthly Digital Health Download, and September's stories all circle the same tension: technology keeps promising to fix healthcare's problems, but just as often it moves them somewhere else, or creates new ones entirely. This week, Halle unpacks a news-heavy month, weighing who actually benefits as markets, algorithms, and AI get closer to our health decisions.We cover:Americans can now bet on clinical trials and FDA regulatory reviews - but do we want that?Meta's massive settlement over harming childrenThe surprising reason AI might be making healthcare more expensive instead of lessA new study on the biggest lever we're not pulling to bend the healthcare cost curveTwo lawsuits rattling a popular wearable and a celebrity-backed mental health startupWhat a widely used drug class reveals about bias in hiring, and the uncomfortable questions that raises⸺
Mifepristone is the only drug that was designed and approved by the FDA to be lethal in purpose. Constitutional expert, lawyer, author, pastor, and founder of Liberty Counsel Mat Staver discusses the important topics of the day with co-hosts and guests that impact life, liberty, and family. To stay informed and get involved, visit LC.org.
The menopause headlines keep contradicting each other — hormones and Alzheimer's, testosterone as a miracle fix, and a week later, “none of it holds up.” In this episode, Dr. Carolyn Moyers reads the actual studies behind this month's headlines and tells you what's real, what got oversold, and what it means for you.In this episode:• Two new studies on hormones and dementia — and the part the headlines skipped: the benefit didn't clearly apply to women in typical, natural menopause• Why the benefit concentrated in women who lost estrogen early — and how that lines up with what guidelines already recommend• Risk reduction vs. prevention: why the difference is the whole point• Testosterone for women: what the newest review shows it truly helps — and why it's not a brain or energy drug• Why there's still no FDA-approved testosterone product for women — what it means to microdose the men's version, and what an approved product would change• The FDA public workshop on testosterone in menopausal women (Sept 17, 2026) — and how to add your voice to the official record• A question you can use on the next headline you seeThis episode is for education and is not medical advice. Talk with your own doctor about what's right for you.• The FDA workshop “Testosterone Use in Menopausal Women” is open to the public: register to watch, and submit a public comment through docket FDA-2026-N-5479 (comments open through Oct 19, 2026). Find it at fda.gov by searching the workshop title.https://event.skywomenshealth.com/world-menopause-day-8703https://event.skywomenshealth.com/world-menopause-day-8703
Leigh Ann welcomes Osteoboost CEO Laura Yecies, who explains the difference between osteopenia and osteoporosis, why knowing your bone-density baseline can be valuable, and why she believes women should become proactive about their bones earlier in life. Bone health is often overlooked until osteoporosis or a fracture occurs, but significant bone loss can begin much earlier—especially during the menopausal transition. Laura also shares her personal experience losing 13% of her bone density between ages 52 and 57 and how it shaped her commitment to finding better preventive options. We explore Osteoboost, an FDA-cleared prescription wearable that uses targeted vibration at the hips and lumbar spine to help reduce bone-density loss in postmenopausal women with osteopenia. The conversation offers a broader look at how screening, exercise, nutrition, medical care, and emerging non-drug interventions may help women preserve bone strength, mobility, and independence as they age.Product Discount Codes + LinksFREE Anxiety First Aid KitLiving Libations: Website (Link gives you 10% off)Broc Shot: Website (Link gives 20% off)Guest InfoOsteoboost - WebsiteLaura Yecies - LinkedInRelated EpisodesPodcast Ep. 238: Dr. Aaron Hartman — Defying Medical Odds, Medical Blindspots & How to Overcome ThemPodcast Ep. 179: Dr. Allie McLane - The Gut, Hormone, and Mind ConnectionPodcast Ep. 177: Dr. Erica Matluck — Are You Missing One of the Four Facets of Healing?Work w/Leigh AnnLearn: What is EVOX Therapy?Book: Schedule a Session or FREE Discovery CallMembership: What is The Healing Alchemy MembershipConnect w/Me & Learn MoreWebsiteInstagramTiktokYoutube
The FDA just expanded Mounjaro's label to include reducing the risk of major adverse cardiovascular events, and the headline is easy to love and easy to misunderstand. We slow it down and translate what the approval actually means for people living with type 2 diabetes, especially those worried about heart attack, stroke, and cardiovascular death.We unpack the exact endpoint behind the claim: MACE, which combines cardiovascular death, non-fatal heart attack, and non-fatal stroke, and we clarify what it is not saying (no, it is not “erasing plaque” or curing atherosclerotic cardiovascular disease). We also explain the real-world nuance around branding and indications: Mounjaro and Zepbound are both tirzepatide, but FDA labels are population-specific, and that can affect clinical decisions and insurance coverage.Then we walk through the Surpass-CVOT cardiovascular outcomes trial in plain English. The key twist is the comparator: tirzepatide was tested against Trulicity (dulaglutide), an active GLP-1 medication with known heart benefit, not placebo. That's why understanding noninferiority vs superiority matters so much. We talk hazard ratios, absolute vs relative risk, and the surprising finding that bigger weight loss and a larger A1C drop did not translate into statistically superior cardiovascular outcomes during the study window.We close with practical guidance and a list of questions you can bring to your own checkup, including whether you have established cardiovascular disease, what makes you “high risk,” whether other cardioprotective meds are already doing the job, how dose changes could affect insulin or blood pressure meds, and what it will actually cost. If you found this helpful, subscribe, share the show with someone managing diabetes risk, and leave us a review so more people can find clear medical context.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski
In part 3 of his new series, Finding a Solution to the Federal Hemp Ban, Jonathan Miller interviews Graham Rigby, President and CEO of the American Herbal Products Association. If you have questions about the episode or ideas for Hemp related topics, email us at hemplegallyspeaking@fbtgibbons.com. Hemp Industry questions covered in the episode: What is the American Herbal Products Association and what is its mission?What does the term "dietary supplement" mean?Which kind of hemp products should be treated as dietary supplements? Which should not?Should impairing hemp products be treated as dietary supplements?What does robust regulation of hemp products look like?What can our listeners do to join in these efforts?
The death toll continues to rise after massive flashfloods in Nepal, FDA has elevated the lettuce recall to it's highest risk, Buc-ee's will only build in red states now, a Steak-N-Shake employee exposed himself in the parking lot, NFL pre-season finished off this weekend, and a man winds up in the hospital after an unfortunate glue incident...
How surgical devices are cleaned and decontaminated determines the efficacy of the sterilization process. For this to be effective, each item must be cleaned according to its instructions for use (IFU). But, how do manufacturers validate cleaning processes for their instruments? In episode 157, host Casey Czarnowski speaks with Dr. William Levia of Medtronic about the manufacturer validation process. Dr. Levia describes the many detailed steps that manufacturers must go through to test cleaning protocols and the reasons behind them. He refers to the different classes of medical devices and discusses the roles of regulatory agencies, standards-setting organizations and testing laboratories. He also introduces listeners to ANSI/AAMI ST98:2022 Cleaning validation of health care products—Requirements for development and validation of a cleaning process for medical devices. Dr. Levia believes in bridging “the standards, the core science and the real-world setting.” Listen to learn more about how instrument manufacturers do their jobs, so we can do ours. ABOUT OUR GUEST Dr. William Levia Global Senior Program Manager for Sterile Processing Medtronic Dr. William Leiva received his PhD in Cybernetics and Statistics from Bucharest University of Economic Studies in 2024 and his MPH in Epidemiology and Health Economics from Andrés Bello National University in 2018. He has worked as a Senior Manager for Scientific Affairs at 3M Healthcare (2008–2023), sterilization and reprocessing subject matter expert at the FDA, and in a leadership role at Medtronic since 2024. He also holds a visiting professorship at Bucharest University of Economic Studies. Dr. Leiva is a recipient of AAMI's Kilmer Grant, serves as a reviewer of peer-reviewed articles, and has presented internationally, including at AAMI eXchange and WFHSS. His research topics include reusable medical device decontamination, terminal sterilization, sterile barrier systems and reprocessing economic epidemiology. Earn CE Now
This episode was sponsored by Cardiff & Apex Performance Longevity Group LLC LightSpeed VT: https://www.lightspeedvt.com/ Dropping Bombs Podcast: https://www.droppingbombs.com/ Today's Dropping Bombs episode delivers hard-won expertise with Shahin Amirpour, the performance and recovery specialist who spent over a decade experimenting on himself with peptides, stem cells, and recovery protocols before he ever sold a single client on any of it. Shahin breaks down why the FDA keeps healing compounds in a gray area, how Chinese labs are flooding the peptide market with knockoffs, and why he's walking away from the Apex Peptides brand he built after copycats diluted it. He's pivoting instead into high-level coaching and a new performance clinic in Newport Beach. Most people chasing better health have no idea if what they're taking has actually been tested on a real person first. This episode will change who you trust with your body, and how you treat it.
The award winning Legal AF Pod helmed by founders Ben Meiselas and Popok keep you informed with riveting commentary about Trump's illegal oil scheme and Canada successful “kiss our ass” strategy; Trump's continued efforts to cover up the USS Abraham Lincoln scandal and destroy the independence of the historic Stars and Stripes media outlet; a federal judge standing between the Kennedy Center and a midnight demolition; Katie Phang's crusading lawsuit against Blanche and the DOJ about the Epstein Documents paying dividends again; a Massachusetts federal judge blocking Trump's latest attempt to screw with Mail in Ballots using the Postal service; a senior status federal judge denying Trump's efforts to absolve himself of the 34 felony convictions for paying off a porn star to win an election, and so much more at the intersection of law and politics. Support Our Sponsors: Nobl: Don't miss NOBL's biggest Sale of the Year! Head to https://NOBLTravel.com for up to 62% off your entire order! #NOBL #ad Spring Sleep: Thanks to today's sponsor, Spring Sleep: eXciteOSA is an FDA-cleared, prescription-only device for primary snoring and mild obstructive sleep apnea. Go to https://springsleep.com/legalaf and unlock 20% off with the code LEGALAF Jiyu Skin Care: The Korean skincare brand everyone is talking about. Our listeners get 20% off their entire order by using code LEGALAF at https://Jiyuskin.com #JiYu #ad Magic Spoon: Save $5 OFF your next order when you go to http://magicspoon.com/LEGALAF Become a member of Legal AF YouTube community: https://www.youtube.com/channel/UCJgZJZZbnLFPr5GJdCuIwpA/join Learn more about the Popok Firm: https://thepopokfirm.com Subscribe to Legal AF Substack: https://michaelpopok.substack.com/subscribe?coupon=2179cd85 Remember to subscribe to ALL the MeidasTouch Network Podcasts: MeidasTouch: https://www.meidastouch.com/tag/meidastouch-podcast Legal AF: https://www.meidastouch.com/tag/legal-af Sidebar with Katie Phang: https://podcasts.apple.com/us/podcast/sidebar-with-katie-phang/id1886801652 The Parnas Perspective: https://podcasts.apple.com/us/podcast/the-parnas-perspective/id1869165949 The Intersection with Michael Popok: https://podcasts.apple.com/us/podcast/the-intersection-with-michael-popok/id1818863274 MissTrial: https://meidasnews.com/tag/miss-trial The PoliticsGirl Podcast: https://www.meidastouch.com/tag/the-politicsgirl-podcast The Ken Harbaugh Show: https://meidasnews.com/tag/the-ken-harbaugh-show The Weekend Show: https://www.meidastouch.com/tag/the-weekend-show Burn the Boats: https://www.meidastouch.com/tag/burn-the-boats Majority 54: https://www.meidastouch.com/tag/majority-54 On Democracy with FP Wellman: https://www.meidastouch.com/tag/on-democracy-with-fpwellman Uncovered: https://www.meidastouch.com/tag/maga-uncovered Five Minute News: https://podcasts.apple.com/us/podcast/five-minute-news/id1471715443 Learn more about your ad choices. Visit megaphone.fm/adchoices
It's Quack Month and Mrs. Pearlmania is taking a look at the hypnotist behind TrimSpa. "It's TrimSpa Baby!" Made famous by the infomercial staring Anna Nicole Smith. It's a very strange journey that takes us from Grokepedia to Syndey Swenney, Cheers, Pokemon and much more. JOIN OUR PATREON COMMUNITY -
© 2020-2026 Ivy Podcast Discovery LLC
